TJPC(SH:600488) Xin Lang Cai Jing·2025-10-31 08:10Core Viewpoint - Tianyao Pharmaceutical (600488.SH) announced that its subsidiary Tianyao Heping received the drug registration certificate for Butorphanol Tartrate Injection from the National Medical Products Administration, which is expected to enhance the company's product pipeline in the narcotic and psychotropic drug sector and positively impact its operating performance [1] Summary by Category Product Approval - The Butorphanol Tartrate Injection is classified as a second-class psychotropic drug, indicated for the treatment of various cancer-related pain and postoperative pain [1] Investment and Development - Tianyao Heping has invested approximately 22 million yuan in the research and development of this product [1] Market Potential - According to data from Minet, the domestic sales revenue for Butorphanol Tartrate Injection is projected to be 1.965 billion yuan in 2023 and 1.899 billion yuan in 2024 [1]